09-June-2026
Corporate News
 
UK’s GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
09-Jun-2026

U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its lung cancer pipeline, in what would be the British drugmaker’s largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price.

News Source:- https://www.cnbc.com/2026/06/09/gsk-in-talks-to-acquire-nuvalent-for-more-than-9-billion.html
 
 
 

Notes:
1. Copyright and ownership of all content from IMC and other IMC sites belongs to IMC except third-party resources
2. Copyright, intellectual property right, ownership or responsibility of error of other content belong to respective sources
3. Please do not reply to this mail

For suggestions and feedback click here.

Disclaimer:
IMC is not responsible for any kind of loss arising due to the information. You are receiving this newsletter because you have subscribed to this service. To unsubscribe click here.
Head Office : IMC Bldg., IMC Marg, Churchgate, Mumbai - 400 020 India  |   Tel : 91-22-22046633  |   Fax : 91-22-22048508 / 22838281
E-Mail : imc@imcnet.org  |   Website : www.imcnet.org